Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors ...

U.S. pharmaceutical company Eli Lilly (LLY) says that the weight-loss pill it is developing should be a candidate for ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly (NYSE:LLY) traded higher Thursday after the pharmaceutical company reported third-quarter results ahead of Wall ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

Also looking to the future, Eli Lilly Chairman and CEO David A. Ricks stated, “We advanced orforglipron through four ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.